Lead nephropathy
نویسندگان
چکیده
منابع مشابه
Bone lead, hypertension, and lead nephropathy.
There is considerable clinical evidence that excessive lead absorption causes renal failure with hypertension and predisposes individuals to hypertension even in the absence of detectable renal failure. Recent analyses of transiliac bone biopsies indicate that unsuspected elevated bone leads may reflect the cause (or contributing cause) of end-stage renal disease in 5% of the European dialysis ...
متن کاملNephropathy in chronic lead poisoning.
This paper presents a study of renal function in I02 patients with lead poisoning admitted to the Occupational Diseases Clinic in Bucharest during the past IO years; nearly half the patients had no history of lead colic. Every possible cause of renal damage, other than lead, was excluded by a careful differential diagnosis. Renal function was investigated by repeated determinations of blood ure...
متن کاملHISTORY IN MEDICINE Lead nephropathy: early leads from descriptive studies
In parallel with civilization, the ubiquitous divalent metal lead was known as early as 4000 BC and the history of lead poisoning dates back 2500 years. Mischievous and relentless mankind lead exposure was captured in The Uncommercial Traveller by Charles Dickens; an old Irish lady told him about the women working in the white lead mills in the east end of London, ‘.some of them gets lead-poiso...
متن کاملEnvironmental Lead Exposure Accelerates Progressive Diabetic Nephropathy in Type II Diabetic Patients
Whether environmental lead exposure has a long-term effect on progressive diabetic nephropathy in type II diabetic patients remains unclear. A total of 107 type II diabetic patients with stage 3 diabetic nephropathy (estimated glomerular filtration rate (eGFR) range, 30-60 mL/min/1.73 m(2)) with normal body lead burden (BLB) (<600 μ g/72 hr in EDTA mobilization tests) and no history of exposur...
متن کاملTherapeutic interruption of advanced glycation in diabetic nephropathy: do all roads lead to Rome?
A major common feature of the chemically disparate compounds that inhibit advanced glycation end product (AGE) accumulation or signaling is their ability to show end-organ protection in experimental models of diabetes complications. The mechanisms by which these AGE- lowering therapies confer their benefits remain unsolved. Is it the reduction in tissue AGE levels per se or the inhibition of do...
متن کاملذخیره در منابع من
با ذخیره ی این منبع در منابع من، دسترسی به آن را برای استفاده های بعدی آسان تر کنید
ژورنال
عنوان ژورنال: Kidney International
سال: 1985
ISSN: 0085-2538
DOI: 10.1038/ki.1985.143